Form 4: BioCryst Pharmaceuticals Executive Charles Gayer Reports Stock Transactions

Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals, reports acquisition of restricted stock units and employee stock options, as well as shares withheld for tax obligations.

Summary

• Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On December 19, 2024, Gayer acquired 125,950 shares of common stock as an annual award of Restricted Stock Units (RSUs) at a price of $0, vesting 25% annually over four years.
• On the same date, 2,461 shares were withheld by BioCryst at $7.39 per share to cover tax obligations related to vesting RSUs.
• Gayer also acquired 260,950 employee stock options (right to buy) at an exercise price of $7.39, vesting 25% annually over four years, expiring on December 19, 2034.
• Following these transactions, Gayer directly owns 423,546 shares of common stock and 260,950 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects standard executive compensation practices and does not contain any overtly positive or negative information.

Positives

• The acquisition of RSUs and stock options by a key executive signals confidence in the company's future performance.
• The vesting schedule of the RSUs and stock options aligns the executive's interests with the long-term success of the company.

Negatives

• The withholding of shares to cover tax obligations reduces the executive's overall holdings, although this is a standard practice.

Risks

• The value of the RSUs and stock options is dependent on the future performance of BioCryst's stock price.
• Changes in tax laws could impact the value of the RSUs and stock options.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a multi-year commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry.
• Vesting schedules of 25% per year over four years are typical for these types of grants.
• Comparable companies such as Vertex Pharmaceuticals and Incyte also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the acquisition of RSUs and stock options by a key executive as a positive sign, aligning management's interests with the company's performance.
• Employees may be motivated by the fact that executives are receiving stock-based compensation, incentivizing them to work towards the company's success.

Key Dates